MarketScreener Homepage > Equities > Nyse > Merck & Co., Inc. MRK

Report

Delayed Nyse - 02/25 04:10:00 pm
74.62	USD		+0.07%

02/25

MERCK : & CO., INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)

02/25

MERCK : Animal Health Completes Acquisition of Poultry Sense Limited

02/25

SECTOR UPDATE : Health Care Stocks Fall Thursday but Mostly Resist Steep Slide

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

02/19/2021	02/22/2021	02/23/2021	02/24/2021	02/25/2021	Date
74.31(c)	74.93(c)	74.54(c)	74.57(c)	74.62(c)	Last
11 820 807	8 217 998	10 401 224	9 388 197	10 407 384	Volume
-1.46%	+0.83%	-0.52%	+0.04%	+0.07%	Change

More quotes

Financials (USD)

Sales 2020	48 177 M - -
Net income 2020	12 094 M - -
Net Debt 2020	15 823 M - -
P/E ratio 2020	15,8x
Yield 2020	3,24%

Sales 2021	51 982 M - -
Net income 2021	14 500 M - -
Net Debt 2021	15 078 M - -
P/E ratio 2021	13,9x
Yield 2021	3,40%

Capitalization	189 B 189 B -
EV / Sales 2020	4,25x
EV / Sales 2021	3,92x
Nbr of Employees	71 000
Free-Float	70,7%

More Financials

Company

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or...

Sector

Pharmaceuticals

Calendar

03/12

Ex-dividend day for

More about the company

Notations Surperformance© of Merck & Co., Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about MERCK & CO., INC.

02/25	MERCK : & CO., INC. Management's Discussion and Analysis of Financial Condition ..	AQ
02/25	MERCK : Animal Health Completes Acquisition of Poultry Sense Limited	BU
02/25	SECTOR UPDATE : Health Care Stocks Fall Thursday but Mostly Resist Steep Slide	MT
02/25	SHAREHOLDER ALERT : WeissLaw LLP Investigates Pandion Therapeutics, Inc.	PR
02/25	SECTOR UPDATE : Health Care Stocks Starting to Lose More Ground This Afternoon	MT
02/25	JPMorgan CEO of Chase consumer banking leaving to head TIAA	RE
02/25	GLOBAL MARKETS LIVE: Moderna, Best Buy, Nvidia…
02/25	SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday	MT
02/25	PANDION THERAPEUTICS : Shares More Than Double Premarket on Takeover by Merck	DJ
02/25	MERCK : to Buy Pandion Therapeutics for $1.85 Billion	DJ
02/25	Merck to Acquire Pandion Therapeutics for $1.85 Billion in All-Cash Deal	MT
02/25	MERCK : to Acquire Pandion Therapeutics	BU
02/24	MERCK : to Present at the Cowen 41st Annual Health Care Conference	BU
02/18	MERCK : AstraZeneca - Independent Data Monitoring Committee Concludes OlympiA Tr..	AQ
02/17	Stocks End Mixed After Strong Retail Sales Report; Verizon, Chevron Lift Dow ..	MT

More news

News in other languages on MERCK & CO., INC.

02/25	MÄRKTE USA/Rentenmarkt schickt Wall Street auf Talfahrt
02/25	MÄRKTE USA/Steigende Renditen schicken Wall Street auf Talfahhrt
02/25	MÄRKTE USA/Abgaben trotz guter US-Daten - Gamestop im Blick
02/25	Les valeurs à suivre aujourd'hui à Wall Street Jeudi 25 février 2021
02/25	MERCK : acquiert la biotech Pandion pour près de deux milliards de dollars

More news

Analyst Recommendations on MERCK & CO., INC.

2020	MERCK : Bernstein Reinstates Merck & Co. at Outperform with $95 Price Target	MT
2020	MERCK : Expects Nearly $2 Billion Covid-19 Revenue Impact in 2020	DJ
2020	Pharma Companies Split on Coronavirus Vaccine Pricing Plans	DJ

More recommendations

Stock Trading Strategies

	MERCK & CO., INC - 2020
Good timing to go long again

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Merck to move COVID-19 treatment into large trials, sees sales recovering this year

More Must read

Chart MERCK & CO., INC.

Duration : Period :

Merck & Co., Inc. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends MERCK & CO., INC.

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bearish	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	23
Average target price	96,76 $
Last Close Price	74,62 $
Spread / Highest target	43,4%
Spread / Average Target	29,7%
Spread / Lowest Target	5,87%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Kenneth C. Frazier	Chairman, President & Chief Executive Officer
Robert M. Davis	CFO & Executive Vice President-Global Services
Sandy Tremps	Vice President-R&D IT CIO
Thomas Henry Glocer	Independent Director
Leslie A. Brun	Lead Independent Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

MERCK & CO., INC.	-8.78%	188 791



JOHNSON & JOHNSON	3.42%	427 844
ROCHE HOLDING AG	-3.87%	281 904
NOVARTIS AG	-5.51%	197 388
ABBVIE INC.	0.17%	189 532
PFIZER INC.	-8.31%	188 042

More Results